Henri H. Roche
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 11, 2021
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Journal: Clinical pharmacology and therapeutics
Published: July 21, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 03, 2020
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 30, 2019
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Journal: Breast cancer research and treatment
Published: April 03, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
Journal: Clinical pharmacology and therapeutics
Published: November 15, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 21, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Journal: The New England journal of medicine
Published: August 16, 2018
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
Journal: Clinical breast cancer
Published: May 04, 2018
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 04, 2018
Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials.
Journal: Clinical breast cancer
Published: April 25, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 13, 2018
Last Updated: 09/26/2026